American Well (NYSE:AMWL) Insider Phyllis Gotlib Sells 4,959 Shares

American Well Corporation (NYSE:AMWL) insider Phyllis Gotlib sold 4,959 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $6.11, for a total transaction of $30,299.49. Following the completion of the transaction, the insider owned 127,151 shares in the company, valued at approximately $776,892.61. This trade represents a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Phyllis Gotlib also recently made the following trade(s):

• On Tuesday, September 2nd, Phyllis Gotlib sold 4,781 shares of American Well stock. The shares were sold at an average price of $6.78, for a total transaction of $32,415.18.

American Well Price Performance

NYSE AMWL opened at $6.34 on Friday. American Well Corporation has a 12 month low of $5.98 and a 12 month high of $12.95. The company has a 50-day moving average of $6.92 and a 200-day moving average of $7.27. The company has a market cap of $102.39 million, a P/E ratio of -0.79 and a beta of 1.26.

American Well (NYSE:AMWL) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($1.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.84) by $0.60. The company had revenue of $70.90 million during the quarter, compared to the consensus estimate of $63.87 million. American Well had a negative net margin of 46.15% and a negative return on equity of 41.99%. American Well has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts anticipate that American Well Corporation will post -9.34 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of American Well from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of American Well in a research report on Saturday, September 27th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, American Well presently has an average rating of “Hold” and an average price target of $9.17.

Institutional Trading of American Well

Several large investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in American Well in the second quarter valued at approximately $39,000. Engineers Gate Manager LP purchased a new position in shares of American Well during the 2nd quarter valued at approximately $101,000. Norges Bank purchased a new position in shares of American Well during the 2nd quarter valued at approximately $250,000. JPMorgan Chase & Co. boosted its stake in shares of American Well by 16.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock valued at $131,000 after buying an additional 2,081 shares during the last quarter. Finally, Senvest Management LLC boosted its stake in shares of American Well by 0.3% during the 2nd quarter. Senvest Management LLC now owns 1,312,852 shares of the company’s stock valued at $11,671,000 after buying an additional 4,497 shares during the last quarter. Institutional investors and hedge funds own 56.05% of the company’s stock.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.